文献速递乳腺癌

乳腺癌患者的治疗与结局:来自EUSOMA乳腺中心网络的横断面研究

Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network.
PubMed 文献 · Eur J Cancer · 2023-11-14

本研究基于EUSOMA数据库81882例乳腺癌患者(诊断时分期0-IV期,中位年龄61岁,范围20-100岁),分析2016年1月至2021年12月期间在13个欧洲国家53个乳腺中心接受治疗的患者。在38119例有远处转移信息的亚组中,多因素分析显示HR-/HER2+和HR-/HER2-亚组比HR+/HER2-亚组远处转移风险更高,Ki67>20%和晚期疾病也携带高风险,放疗为远处转移的保护因素。

要点

  • HR-/HER2+和HR-/HER2-亚组远处转移风险高于HR+/HER2-亚组。
  • Ki67>20%和晚期疾病与远处转移高风险相关。
  • 放疗是远处转移的保护因素。

核心结论

  • 大型患者数据库可提供信息流以减少临床实践中的不确定性。
  • 数据库参数需要动态更新以进行结局监测。
  • 应加入分子预后因素、基因表达特征、肿瘤浸润淋巴细胞和循环肿瘤DNA。

研究设计与样本

  • 横断面研究,分析EUSOMA数据库中81882例乳腺癌患者(诊断时分期0-IV期;中位年龄61岁;范围20-100岁)。
  • 所有患者在2016年1月至2021年12月期间于13个欧洲国家53个EUSOMA认证流程内的乳腺中心接受治疗。
  • 病例按HR+/HER2-、HR+/HER2+、HR-/HER2+或HR-/HER2-分类分析。
  • 远处转移的单因素和多因素分析在38119例有是否发生远处转移信息的亚组中进行。

主要发现

  • 多因素分析中,HR-/HER2+和HR-/HER2-亚组相比HR+/HER2-与更高的远处转移风险相关。
  • Ki67>20%和晚期疾病也携带高风险。
  • 放疗显示为远处转移的保护因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The present study was designed to describe tumour features and treatments for patients with breast cancer. It also aimed at assessing the risk of distant metastases in relation to biological profiles, disease stages and treatment. METHODS: Data were analysed from 81,882 patients in the EUSOMA database (disease stages at diagnosis 0-IV; median age 61 years; range 20-100 years). All patients were treated between January 2016 and December 2021 in 53 Breast Centres within the EUSOMA certification process in 13 European countries. Cases were classified as HR+ /HER2-, HR+ /HER2 + , HR-/HER2 + or HR-/HER2- and data were analysed accordingly. RESULTS: Univariable and multivariable analyses for distant metastases were conducted on a subset of 38,119 cases with information on whether or not they had developed them. Potential determinants included sub-group type, Ki67 value, disease stage, adjuvant systemic therapies and post-operative radiation therapy. In multivariable analysis, the HR-/HER2 + and HR-/HER2- sub-groups were associated with a higher risk of distant metastases than HR+ /HER2-. Ki67 > 20 % and advanced stage disease also carried a high risk. Radiation therapy emerged as a protective factor against distant metastases. CONCLUSIONS: Present results show a large patient database offers an information stream that can be applied to reduce uncertainties in clinical practice. Database parameters need to be updated dynamically for outcome monitoring. Molecular prognostic factors, gene-expression signatures, tumour-infiltrating lymphocytes and circulating tumoral DNA should be added.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Aristei C, Tomatis M, Antonio Ponti, et al. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network. Eur J Cancer. 2023. PMID: 37995597. doi:10.1016/j.ejca.2023.113438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。